Prelude Therapeutics Files 8-K
Ticker: PRLD · Form: 8-K · Filed: Dec 11, 2024 · CIK: 1678660
Sentiment: neutral
Topics: filing, financials
TL;DR
Prelude Therapeutics filed a routine 8-K with updated financials and exhibits.
AI Summary
On December 11, 2024, Prelude Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. No new financial figures or significant business updates were detailed in the provided excerpt.
Why It Matters
This filing serves as a standard disclosure for Prelude Therapeutics Inc., providing the SEC with updated financial statements and exhibits as required by regulations.
Risk Assessment
Risk Level: low — The filing appears to be a standard disclosure of financial statements and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Prelude Therapeutics Inc. (company) — Registrant
- December 11, 2024 (date) — Date of Report
- Delaware (location) — State of Incorporation
- 175 Innovation Boulevard (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Prelude Therapeutics Inc.?
The primary purpose of this 8-K filing is to report other events and to provide financial statements and exhibits as of December 11, 2024.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is December 11, 2024.
In which state is Prelude Therapeutics Incorporated organized?
Prelude Therapeutics Incorporated is organized in Delaware.
What is the principal executive office address for Prelude Therapeutics Inc.?
The principal executive office address for Prelude Therapeutics Inc. is 175 Innovation Boulevard, Wilmington, Delaware, 19805.
Does this filing indicate any significant changes in Prelude Therapeutics' business operations or financial condition?
Based on the provided excerpt, this 8-K filing primarily concerns financial statements and exhibits, and does not detail specific significant changes in business operations or financial condition.
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-12-11 07:45:09
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share PRLD Nasdaq Glo
Filing Documents
- prld-20241211.htm (8-K) — 48KB
- prld-ex99_1.htm (EX-99.1) — 35KB
- img268059179_0.jpg (GRAPHIC) — 6KB
- 0000950170-24-135212.txt ( ) — 240KB
- prld-20241211.xsd (EX-101.SCH) — 49KB
- prld-20241211_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On December 11, 2024, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing the presentation of the first interim clinical data from its ongoing open-label, dose-escalation trial of PRT2527, a potent and highly selective CDK9 inhibitor, as monotherapy and in combination with zanubrutinib in patients with relapsed/refractory lymphoid malignancies. The data were presented at a poster session of the 66th American Society of Hematology Annual Meeting in San Diego, California. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRELUDE THERAPEUTICS INCORPORATED Date: December 11, 2024 By: /s/ Bryant Lim Bryant Lim Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer